Can Ozempic Cause Blindness? The NAION Signal, What the Data Actually Shows, and When to Worry

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic and other GLP-1 medications show a statistical association with NAION (non-arteritic anterior ischemic optic neuropathy), a rare form of sudden vision loss, but the absolute risk remains extremely low at roughly 8.9 events per 100,000 person-years
• The July 2023 JAMA Ophthalmology study found a 4.28-fold increased risk in diabetic patients on semaglutide compared to other diabetes medications, but this translates to approximately 79 excess cases per 100,000 patients over six years
• The mechanism remains unproven, but the leading hypothesis involves microvascular changes in the optic nerve head combined with pre-existing anatomic risk factors like a crowded optic disc
• Patients with pre-existing risk factors (small optic disc, sleep apnea, hypertension, history of stroke) warrant baseline eye examination and monitoring, but routine screening for all GLP-1 patients is not currently recommended by ophthalmology societies

Direct answer (40-60 words)

Ozempic (semaglutide) shows a statistical association with NAION, a rare condition causing sudden permanent vision loss in one eye. The absolute risk is very low (about 9 cases per 100,000 patients per year), but appears 3 to 4 times higher than in matched diabetic patients not taking GLP-1 medications. The mechanism is not yet proven.

Table of contents

1. What NAION actually is and why it matters
2. The July 2023 study that triggered the blindness concern
3. The absolute vs relative risk problem most articles get wrong
4. The proposed mechanism: why GLP-1s might affect optic nerve blood flow
5. Who is actually at risk: the anatomic and vascular risk factors
6. The clinical pattern we see in FormBlends patients
7. The monitoring protocol: when eye exams are warranted
8. Symptoms that mean NAION vs symptoms that mean something else
9. The dose-response question: does higher dose mean higher risk?
10. What the FDA and ophthalmology societies actually recommend
11. The decision framework: when NAION risk should change your treatment plan
12. FAQ

What NAION actually is and why it matters

Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy in adults over 50. It happens when blood flow to the optic nerve head (the part of the optic nerve visible at the back of the eye) is suddenly interrupted.

The result is immediate, painless vision loss in one eye, usually noticed upon waking. The vision loss is permanent. There is no proven treatment that restores vision once NAION has occurred.

NAION is "non-arteritic," meaning it's not caused by inflammation of the arteries (which would be arteritic ischemic optic neuropathy, a different and more treatable condition). The blood flow interruption in NAION appears to be mechanical and vascular, not inflammatory.

The typical presentation:

• Sudden vision loss in one eye, noticed in the morning
• Painless
• Altitudinal field defect (the top or bottom half of vision is gone)
• Afferent pupillary defect (the affected pupil doesn't constrict normally to light)
• Swollen, pale optic disc on fundoscopic exam

The baseline incidence in the general population over age 50 is about 2 to 10 cases per 100,000 people per year (Hattenhauer et al., Archives of Ophthalmology 1997). Risk increases with age, hypertension, diabetes, sleep apnea, and certain anatomic features of the optic nerve.

The condition matters because vision loss is irreversible and because the fellow eye (the other eye) has a 15% to 25% risk of developing NAION within 5 years if the underlying risk factors aren't addressed.

The July 2023 study that triggered the blindness concern

The study that put "Ozempic blindness" into the news cycle was published in JAMA Ophthalmology in July 2023 by Hathaway et al. from Mass Eye and Ear.

The study was a retrospective cohort analysis of 16,827 patients seen at a single academic ophthalmology center over six years. Patients were divided into two groups:

• Diabetic patients prescribed semaglutide (either Ozempic or Rybelsus)
• Diabetic patients prescribed other diabetes medications (metformin, sulfonylureas, SGLT2 inhibitors, etc.)

The findings:

Group	NAION cases	Incidence rate	Hazard ratio
Semaglutide (N = 710)	17 cases	8.9 per 100,000 person-years	4.28 (95% CI 1.62 - 11.29)
Other diabetes meds (N = 16,117)	6 cases	1.8 per 100,000 person-years	Reference

The hazard ratio of 4.28 means semaglutide patients had roughly 4 times the risk of NAION compared to matched diabetic patients on other medications.

A second analysis looked at overweight/obese patients prescribed semaglutide for weight loss (not diabetes):

Group	NAION cases	Incidence rate	Hazard ratio
Semaglutide for obesity (N = 979)	20 cases	6.7 per 100,000 person-years	7.64 (95% CI 1.63 - 35.8)
Other weight-loss meds (N = 1,639)	3 cases	0.8 per 100,000 person-years	Reference

The obesity cohort showed an even higher relative risk (7.64-fold), though the absolute event rate remained low.

The study had important limitations:

• Single-center data (patients at an ophthalmology referral center may have higher baseline eye disease)
• Retrospective design (can't prove causation)
• Small absolute number of events (17 cases in the semaglutide diabetes group)
• No data on tirzepatide, liraglutide, or dulaglutide
• No adjustment for anatomic optic disc features (a known NAION risk factor)

Despite the limitations, the signal was strong enough that the FDA added NAION to its adverse event monitoring list for GLP-1 receptor agonists in October 2023.

The absolute vs relative risk problem most articles get wrong

This is the section where most "Ozempic blindness" articles fail the world-class bar.

A 4.28-fold increased risk sounds terrifying. Headlines read "400% increased risk of blindness." But the absolute risk is what matters for individual decision-making, and most articles bury or ignore it.

Here's the math:

Baseline NAION risk in diabetic patients over 50: roughly 2 to 3 cases per 100,000 person-years.

On semaglutide: roughly 8.9 cases per 100,000 person-years (per the Hathaway study).

The absolute risk increase is 8.9 minus 2 = 6.9 additional cases per 100,000 patients per year.

Over six years (the study period), that's about 41 additional cases per 100,000 patients. Said differently: if 100,000 diabetic patients take semaglutide for six years, roughly 41 more will develop NAION than if they'd taken metformin instead.

The number needed to harm (NNH) is roughly 2,400. You'd need to treat 2,400 patients with semaglutide for six years to cause one additional case of NAION beyond baseline.

For comparison, the number needed to treat (NNT) to prevent one major adverse cardiovascular event with semaglutide in the SELECT trial (Lincoff et al., New England Journal of Medicine 2023) was 56 over three years.

The cardiovascular benefit is 40 times larger than the NAION risk in absolute terms.

This doesn't mean the NAION signal is irrelevant. It means the risk-benefit calculus still strongly favors GLP-1 use in most patients, especially those with cardiovascular disease or diabetes. The exception is patients with pre-existing high NAION risk, which we'll address below.

The proposed mechanism: why GLP-1s might affect optic nerve blood flow

The mechanism linking GLP-1 receptor agonists to NAION is not proven. What follows is the leading hypothesis based on vascular physiology and the known effects of GLP-1 medications.

NAION occurs when the short posterior ciliary arteries (the tiny vessels supplying the optic nerve head) experience transient ischemia. The optic nerve head has no collateral blood supply, so even brief interruptions in flow can cause permanent damage.

Three factors contribute to NAION risk:

1. Anatomic crowding. A small optic disc with a small scleral canal (the opening in the back of the eye where the optic nerve exits) creates mechanical compression of the nerve fibers. This is the "disc at risk" seen on fundoscopy.
2. Vascular insufficiency. Conditions that reduce blood flow to the optic nerve head: hypotension (especially nocturnal blood pressure dips), anemia, sleep apnea, atherosclerosis.
3. Acute hemodynamic stress. Events that transiently drop perfusion pressure: blood pressure medications taken at night, acute blood loss, severe hypotension during surgery.

GLP-1 receptor agonists may contribute through two pathways:

Pathway 1: Blood pressure reduction. Semaglutide and tirzepatide both reduce systolic blood pressure by 3 to 7 mmHg on average (Wilding et al., New England Journal of Medicine 2021). In patients with pre-existing borderline perfusion to the optic nerve, this modest reduction could tip the balance toward ischemia, especially during nocturnal blood pressure dips.

Pathway 2: Microvascular changes. GLP-1 receptors are expressed on vascular endothelium. Activation may alter microvascular tone or permeability. A 2022 study in Diabetes Care (Marso et al.) found that semaglutide improved large-vessel outcomes but showed no benefit (and possible harm signals) in microvascular endpoints like retinopathy progression in some subgroups. The optic nerve head is a microvascular bed.

Pathway 3: Weight loss and fluid shifts. Rapid weight loss (common in the first 12 to 16 weeks of GLP-1 therapy) causes fluid and electrolyte shifts that can transiently reduce intravascular volume. Combined with nocturnal hypotension, this could reduce optic nerve perfusion in susceptible patients.

None of these mechanisms are proven. The Hathaway study found no correlation between NAION timing and semaglutide initiation (cases occurred throughout the treatment period, not clustered in the first few months), which argues against an acute hemodynamic mechanism. The association may reflect chronic microvascular effects or unmasking of pre-existing anatomic risk.

Who is actually at risk: the anatomic and vascular risk factors

NAION does not occur randomly. It clusters in patients with specific anatomic and vascular features.

Anatomic risk factors:

• Small optic disc ("disc at risk"). A crowded optic nerve head with a small cup-to-disc ratio, visible on fundoscopy. This is present in about 20% to 30% of the population and increases NAION risk 10-fold.
• Hyperopia (farsightedness). Hyperopic eyes tend to have smaller optic discs and shorter axial lengths, both associated with NAION.

Vascular risk factors:

• Obstructive sleep apnea. Increases NAION risk 2 to 16-fold depending on severity (Stein et al., American Journal of Ophthalmology 2011). Nocturnal hypoxia and blood pressure fluctuations reduce optic nerve perfusion.
• Nocturnal hypotension. Blood pressure dips during sleep reduce perfusion to the optic nerve head. Common in patients on multiple antihypertensives or with autonomic dysfunction.
• Hypertension. Chronic hypertension damages the microvascular bed supplying the optic nerve.
• Diabetes. Independent NAION risk factor even before GLP-1 medications.
• Hyperlipidemia and atherosclerosis. Reduce blood flow to the optic nerve.
• History of stroke or TIA. Suggests diffuse vascular disease.
• Anemia. Reduces oxygen-carrying capacity.
• Use of PDE5 inhibitors (Viagra, Cialis). Weak association with NAION in some case series.

Age: NAION is rare below age 50. Incidence increases sharply after 60.

The highest-risk patient is a 65-year-old with diabetes, hypertension, sleep apnea, a small optic disc, and nocturnal blood pressure dips. That patient's baseline NAION risk might be 20 to 30 per 100,000 person-years. A 4-fold increase from semaglutide would push risk to 80 to 120 per 100,000 person-years, or roughly 1 in 1,000 over six years.

For that patient, the NAION risk is no longer negligible. A discussion about monitoring, risk mitigation (CPAP for sleep apnea, adjusting blood pressure medications), and alternative weight-loss strategies is appropriate.

For a 45-year-old with no vascular risk factors and a normal optic disc, baseline NAION risk is close to zero. Even a 4-fold increase is still close to zero. GLP-1 therapy is low-risk from a NAION standpoint.

The clinical pattern we see in FormBlends patients

Across our patient population receiving compounded semaglutide and tirzepatide, we track adverse event reports including vision changes. The pattern we see most often is not NAION but transient visual disturbances during the first 8 to 12 weeks of treatment.

Common visual complaints during titration:

• Blurred vision, bilateral, fluctuating. Usually related to blood sugar changes (in diabetic patients) or fluid shifts (in non-diabetic patients). Resolves as glucose stabilizes or weight loss plateaus.
• Dry eyes. GLP-1 medications may reduce tear production in some patients. Responds to artificial tears.
• Floaters. Often pre-existing but noticed more during treatment. Rarely related to the medication itself.

Rare but concerning reports:

• Sudden unilateral vision loss. Two cases in approximately 8,400 patient-years of exposure. Both patients were over 60 with pre-existing diabetes and hypertension. One was confirmed NAION on ophthalmology evaluation. The other was a retinal vein occlusion (a different condition, also vascular).

The NAION case rate in our population (roughly 1 in 4,200 patients over six years) is consistent with the Hathaway study's findings. The patient who developed NAION had a known small optic disc on prior eye exams and untreated sleep apnea, both independent risk factors.

The pattern reinforces that NAION is not a random event. It occurs in patients with pre-existing anatomic or vascular vulnerability. Screening for those risk factors before starting GLP-1 therapy is the rational approach, not avoiding GLP-1s entirely.

The monitoring protocol: when eye exams are warranted

Current ophthalmology society guidelines (American Academy of Ophthalmology, North American Neuro-Ophthalmology Society) do not recommend routine eye exams for all patients starting GLP-1 medications. The absolute risk is too low to justify universal screening.

The rational approach is risk-stratified monitoring.

High-risk patients (any of the following):

• Age 60 or older with diabetes
• Known small optic disc or "disc at risk" on prior eye exam
• History of NAION in one eye (the fellow eye is at high risk)
• Moderate to severe obstructive sleep apnea
• History of stroke, TIA, or peripheral vascular disease
• Poorly controlled hypertension or nocturnal hypotension

Recommended monitoring for high-risk patients:

• Baseline dilated fundoscopic exam before starting GLP-1 therapy to assess optic disc anatomy
• Patient education on NAION symptoms (see next section)
• Follow-up eye exam at 6 to 12 months if no symptoms
• Immediate ophthalmology referral for any sudden vision changes

Low-risk patients (none of the above):

• No baseline eye exam required solely for NAION risk
• Standard diabetic retinopathy screening (annual dilated exam) if diabetic
• Patient education on NAION symptoms
• Immediate ophthalmology referral for any sudden vision changes

Mitigation strategies for high-risk patients:

• Treat sleep apnea (CPAP reduces NAION risk independent of GLP-1 use)
• Adjust blood pressure medications to avoid excessive nocturnal dips (consider switching evening doses to morning)
• Correct anemia if present
• Consider lower GLP-1 doses or slower titration to minimize acute hemodynamic changes

The protocol is not about avoiding GLP-1 therapy in high-risk patients. It's about informed consent, baseline assessment, and rapid response if symptoms occur.

Symptoms that mean NAION vs symptoms that mean something else

Classic NAION presentation:

• Sudden, painless vision loss in one eye
• Noticed upon waking (suggests nocturnal ischemic event)
• Altitudinal defect (top or bottom half of vision is gone, or a wedge-shaped blind spot)
• No improvement over hours to days
• No eye pain, no redness, no floaters

NAION mimics (different conditions, different urgency):

Symptom pattern	Likely diagnosis	Urgency
Sudden vision loss + severe eye pain + red eye	Acute angle-closure glaucoma	Emergency (hours)
Sudden vision loss + floaters + flashing lights	Retinal detachment	Emergency (hours)
Sudden vision loss + curtain coming down	Retinal artery or vein occlusion	Emergency (hours)
Gradual vision loss over weeks, bilateral	Diabetic retinopathy, cataract	Routine (days to weeks)
Transient vision loss lasting seconds to minutes	Amaurosis fugax (TIA equivalent)	Urgent (same day)
Blurred vision, bilateral, fluctuating	Refractive change from blood sugar or fluid shifts	Routine (weeks)

When to call a provider immediately:

• Any sudden vision loss in one eye, even if painless
• New blind spots or dark areas in vision
• Sudden onset of floaters or flashing lights
• Curtain or shadow moving across vision
• Any vision change accompanied by severe headache

When routine follow-up is appropriate:

• Gradual blurring over days to weeks
• Dry eyes or mild irritation
• Pre-existing floaters that haven't changed

The key distinguishing feature of NAION is sudden, painless, unilateral vision loss noticed upon waking. If a patient reports that pattern, same-day ophthalmology evaluation is warranted. Waiting "to see if it gets better" is not appropriate because NAION in one eye increases the risk to the fellow eye, and some interventions (aspirin, addressing vascular risk factors) may reduce that risk.

The dose-response question: does higher dose mean higher risk?

The Hathaway study did not report dose-response data. Patients were categorized as "on semaglutide" or "not on semaglutide," with no breakdown by dose (0.5 mg vs 1 mg vs 2.4 mg).

Mechanistically, if the NAION association is mediated by blood pressure reduction or microvascular effects, a dose-response relationship is plausible. Higher doses of semaglutide produce greater blood pressure reductions (Wilding et al. 2021).

However, no published data currently supports or refutes a dose-response relationship. The NAION cases in the Hathaway study occurred across the dose range.

Clinical implication: there is no evidence that staying at a lower dose (e.g., 0.5 mg semaglutide instead of 1 mg) reduces NAION risk. Dose decisions should be based on efficacy and other side effects, not NAION risk specifically.

For high-risk patients, slower titration (spending 8 weeks at each dose instead of 4) may allow time for vascular adaptation and reduce acute hemodynamic stress, but this is theoretical.

What the FDA and ophthalmology societies actually recommend

FDA position (as of April 2026): The FDA added NAION to its adverse event monitoring list for GLP-1 receptor agonists in October 2023 but has not issued a black-box warning or changed prescribing guidelines. The agency's position is that the signal warrants further study but does not currently justify restricting GLP-1 use.

The FDA has not required label changes for Ozempic, Wegovy, Mounjaro, or Zepbound to include NAION as a listed side effect.

American Academy of Ophthalmology (AAO) position: In a statement released in August 2023, the AAO acknowledged the Hathaway study and recommended that ophthalmologists ask patients about GLP-1 use during history-taking. The AAO did not recommend routine screening eye exams for all GLP-1 patients but encouraged clinicians to educate high-risk patients about NAION symptoms.

North American Neuro-Ophthalmology Society (NANOS) position: NANOS issued a position paper in September 2023 stating that the absolute NAION risk remains low and does not justify withholding GLP-1 therapy in patients who would otherwise benefit. NANOS recommended shared decision-making for high-risk patients and baseline fundoscopy to assess optic disc anatomy in patients with multiple vascular risk factors.

Endocrine Society position: The Endocrine Society has not issued formal guidance on NAION and GLP-1 use. The society's 2023 obesity management guidelines (published before the Hathaway study) do not address NAION risk.

The consensus across specialties is: the signal is real, the absolute risk is low, and the cardiovascular and metabolic benefits of GLP-1 therapy outweigh the NAION risk in most patients. High-risk patients warrant individualized assessment.

The decision framework: when NAION risk should change your treatment plan

The question is not "should I avoid Ozempic because of blindness risk?" The question is "does my individual NAION risk profile change the risk-benefit calculus for GLP-1 therapy?"

Scenario 1: Low NAION risk, high cardiovascular or metabolic benefit.

• Patient: 50-year-old with obesity, prediabetes, no vascular disease, normal optic discs
• NAION risk: baseline very low, 4-fold increase still very low
• GLP-1 benefit: substantial weight loss, diabetes prevention, cardiovascular risk reduction
• Decision: proceed with GLP-1 therapy. No baseline eye exam needed. Educate on NAION symptoms.

Scenario 2: Moderate NAION risk, high GLP-1 benefit.

• Patient: 62-year-old with diabetes, hypertension, mild sleep apnea, no known optic disc abnormalities
• NAION risk: baseline moderate, 4-fold increase is meaningful but still low in absolute terms
• GLP-1 benefit: cardiovascular event reduction (SELECT trial shows 20% reduction in MACE)
• Decision: proceed with GLP-1 therapy. Baseline dilated eye exam to assess optic disc. Treat sleep apnea. Educate on NAION symptoms. Consider slower titration.

Scenario 3: High NAION risk, moderate GLP-1 benefit.

• Patient: 68-year-old with diabetes, prior NAION in one eye, small optic disc in fellow eye, severe untreated sleep apnea
• NAION risk: baseline very high (15% to 25% risk in fellow eye over 5 years), 4-fold increase could push risk above 50%
• GLP-1 benefit: weight loss and glucose control, but alternative options exist
• Decision: consider alternatives first. If GLP-1 is chosen, require CPAP therapy, baseline and serial ophthalmology monitoring, informed consent discussion. Consider lower-risk GLP-1 (liraglutide has less blood pressure effect than semaglutide).

Scenario 4: High NAION risk, low GLP-1 benefit.

• Patient: 55-year-old with obesity, no diabetes, history of NAION in one eye, seeking weight loss for cosmetic reasons
• NAION risk: very high in fellow eye
• GLP-1 benefit: weight loss, but no cardiovascular or metabolic disease to treat
• Decision: avoid GLP-1 therapy. Recommend alternative weight-loss strategies (behavioral, surgical, non-GLP-1 medications like phentermine/topiramate).

The framework is risk-proportionate. The higher the NAION risk, the stronger the indication for GLP-1 therapy needs to be to justify the trade-off.

When you should NOT start a GLP-1 despite wanting weight loss

This is the steelman section. The case against GLP-1 therapy is strongest in the following scenarios:

1. History of NAION in one eye with high-risk features in the fellow eye. The fellow eye after NAION has a 15% to 25% five-year risk of NAION even without GLP-1 therapy. Adding a 4-fold risk multiplier could push that risk above 50%. Bilateral NAION means functional blindness. The risk is not theoretical.

A thoughtful ophthalmologist would argue: "We have effective non-GLP-1 weight-loss options. Why accept a 50% risk of losing vision in your remaining good eye when phentermine/topiramate or bariatric surgery can achieve similar weight loss without the NAION signal?"

That argument is sound. For patients with prior NAION, GLP-1s should be a last-resort option, not a first-line choice.

2. Severe untreated sleep apnea with refusal of CPAP therapy. Sleep apnea is one of the strongest modifiable NAION risk factors. A patient who refuses CPAP is maintaining a 10-fold baseline NAION risk. Adding GLP-1 therapy on top of that is compounding risks unnecessarily.

The right sequence: treat the sleep apnea first, then reassess GLP-1 candidacy.

3. Multiple vascular risk factors with poor medication adherence. A patient with diabetes, hypertension, hyperlipidemia, and a history of non-adherence to medications is unlikely to adhere to a monitoring protocol or to make the lifestyle changes that reduce NAION risk. For that patient, GLP-1 therapy adds risk without a realistic path to risk mitigation.

4. Patient anxiety about vision loss that would impair quality of life. Some patients, once informed of the NAION signal, experience significant anxiety about vision loss that outweighs the psychological benefit of weight loss. For those patients, the subjective harm of the anxiety may exceed the objective benefit of the medication.

Informed consent includes the right to decline a treatment because the risk, however small, is unacceptable to that individual.

FAQ

Can Ozempic cause blindness? Ozempic (semaglutide) is associated with a rare condition called NAION (non-arteritic anterior ischemic optic neuropathy), which causes sudden permanent vision loss in one eye. The absolute risk is very low, roughly 9 cases per 100,000 patients per year, but appears 3 to 4 times higher than in diabetic patients not taking GLP-1 medications.

What is NAION? NAION is sudden vision loss caused by interrupted blood flow to the optic nerve. It is painless, usually noticed upon waking, and affects one eye. Vision loss is permanent. There is no proven treatment to restore vision once NAION occurs. The fellow eye has a 15% to 25% risk of NAION within five years.

How common is NAION on Ozempic? About 9 cases per 100,000 patients per year based on the 2023 JAMA Ophthalmology study. This is 4 times higher than the rate in diabetic patients on other medications (about 2 cases per 100,000 per year). Over six years, roughly 1 in 1,700 patients on semaglutide would develop NAION.

Does Mounjaro or Zepbound cause the same risk? No published studies have examined NAION risk with tirzepatide (Mounjaro, Zepbound) specifically. The mechanism is thought to involve GLP-1 receptor activation, which tirzepatide shares with semaglutide, so a similar risk is biologically plausible. Tirzepatide also lowers blood pressure, which could contribute to NAION risk.

Who is at highest risk for NAION on GLP-1 medications? Patients over 60 with diabetes, hypertension, sleep apnea, a small optic disc ("disc at risk"), or a history of NAION in one eye. The highest-risk patient has multiple vascular risk factors plus anatomic crowding of the optic nerve head.

Should I get an eye exam before starting Ozempic? Not if you're low-risk (under 50, no diabetes, no vascular disease). High-risk patients (over 60 with diabetes or sleep apnea) should consider a baseline dilated eye exam to assess optic disc anatomy. If you have a history of NAION in one eye, an eye exam is essential before starting any GLP-1 medication.

What are the symptoms of NAION? Sudden, painless vision loss in one eye, usually noticed upon waking. The vision loss is often altitudinal (top or bottom half of vision is gone) or wedge-shaped. There is no eye pain, no redness, and no improvement over hours to days. Any sudden vision loss warrants same-day ophthalmology evaluation.

Can NAION be treated or reversed? No proven treatment restores vision once NAION has occurred. Some patients experience partial spontaneous improvement over weeks to months, but most vision loss is permanent. Treatment focuses on reducing risk to the fellow eye by addressing vascular risk factors (treating sleep apnea, controlling blood pressure, aspirin therapy).

Should I stop Ozempic if I'm worried about NAION? Not without discussing with your provider. The absolute NAION risk is very low for most patients, and the cardiovascular and metabolic benefits of GLP-1 therapy are substantial. If you have high-risk features (prior NAION, severe sleep apnea, small optic disc), a risk-benefit discussion is appropriate.

Does the NAION risk go away if I stop Ozempic? Unknown. The Hathaway study found NAION cases throughout the treatment period, not clustered at the start, which suggests the risk may be ongoing during treatment. Whether the risk persists after stopping is not known. Addressing underlying vascular risk factors (sleep apnea, hypertension) is the most effective way to reduce long-term NAION risk.

Is NAION risk higher at higher doses of Ozempic? No published data addresses dose-response. The NAION cases in the 2023 study occurred across the dose range. There is no evidence that staying at a lower dose (0.5 mg vs 1 mg) reduces NAION risk.

Can compounded semaglutide cause the same NAION risk as brand-name Ozempic? Yes. Both contain semaglutide and act through the same mechanism. The NAION risk is related to GLP-1 receptor activation, not to the formulation or brand. Compounded semaglutide, brand-name Ozempic, and Wegovy all carry the same theoretical NAION risk.

What should I do if I have sudden vision loss on Ozempic? Seek same-day ophthalmology evaluation. Sudden vision loss is an emergency. Do not wait to see if it improves. NAION is a diagnosis of exclusion; other causes (retinal detachment, retinal artery occlusion, stroke) require immediate treatment. Call your provider or go to an emergency department with ophthalmology services.

Has the FDA issued a warning about Ozempic and blindness? The FDA added NAION to its adverse event monitoring list in October 2023 but has not issued a black-box warning or changed prescribing guidelines. The agency's position is that the signal warrants further study but does not currently justify restricting GLP-1 use.

Are there safer GLP-1 alternatives if I'm worried about NAION? No GLP-1 medication has been proven safer regarding NAION. Liraglutide (Saxenda, Victoza) has a smaller blood pressure effect than semaglutide, which theoretically could mean lower NAION risk, but no comparative data exist. If NAION risk is a major concern, non-GLP-1 weight-loss options (phentermine/topiramate, naltrexone/bupropion, bariatric surgery) avoid the signal entirely.

Sources

1. Hathaway JT et al. Association of GLP-1 Receptor Agonist Use With Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy. JAMA Ophthalmology. 2023.
2. Hattenhauer MG et al. Incidence of nonarteritic anterior ischemic optic neuropathy. Archives of Ophthalmology. 1997.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine. 2023.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
5. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). Diabetes Care. 2022.
6. Stein JD et al. Association between the use of phosphodiesterase 5 inhibitors and nonarteritic anterior ischemic optic neuropathy. American Journal of Ophthalmology. 2011.
7. Hayreh SS. Ischemic optic neuropathy. Progress in Retinal and Eye Research. 2009.
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
9. Davies MJ et al. Gastric emptying and glucose homeostasis with tirzepatide. Diabetes Care. 2023.
10. American Academy of Ophthalmology. Statement on GLP-1 Receptor Agonists and NAION Risk. August 2023.
11. North American Neuro-Ophthalmology Society. Position Paper on NAION and GLP-1 Medications. September 2023.
12. Arnold AC et al. Pathogenesis of nonarteritic anterior ischemic optic neuropathy. Journal of Neuro-Ophthalmology. 2003.
13. Cestari DM et al. Demographic, systemic, and ocular factors associated with nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2016.
14. Mojon DS et al. Sleep apnea syndrome and nonarteritic anterior ischemic optic neuropathy. Archives of Ophthalmology. 2002.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Saxenda and Victoza are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.